Drug intelligence / Profile preview

Risontin

Development stage: Unknown
Lead developer: Sampharindo Retroviral Indonesia
Modality: Small Molecules
Administration: Oral

Overview

**Risontin** is an oral fixed-dose antitubercular combination containing **rifapentine 300 mg** and **isoniazid 300 mg** per film-coated tablet. It is marketed in Indonesia by Sampharindo Retroviral Indonesia for treatment of latent tuberculosis infection caused by *Mycobacterium tuberculosis*. Rifapentine is a rifamycin antibacterial that inhibits mycobacterial DNA-dependent RNA polymerase, while isoniazid is a prodrug that inhibits InhA-dependent mycolic-acid synthesis after activation in mycobacteria.

Brand names: Risontin
Other names: isoniazid + rifapentinerifapentine + isoniazid

Targets

FabI (Enoyl-acyl carrier protein reductase FabI)rpoB (DNA-directed RNA polymerase subunit beta)

Beyond the preview

Go deeper on Risontin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Risontin.

Explore the full profile